Medical Xpress September 11, 2024
Alison McCook, The Philadelphia Inquirer

You don’t often see a “science day” in a Philadelphia courtroom. But that’s exactly what happened last week in a potentially ground-shifting legal fight brought by patients against the manufacturers of blockbuster drugs for diabetes and weight loss.

At the heart of the case are the drugs in question: Ozempic, Wegovy, and others that work in a similar way. The drugs—which help regulate blood sugar levels and reduce —have been hailed as a “miracle,” and have become a hot commodity, used by one in eight U.S. adults, according to a recent poll.

Now, some patients are suing Novo Nordisk and Eli Lilly, the manufacturers of the medications, claiming they were not adequately warned of the potentially serious side effects...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Clinical Trials, Pharma / Biotech, Trends
How Life Sciences Can Drive Innovation And Sustainability In Returns Management
How Americans feel about weight-loss drugs, in 3 charts
Tariffs on China threaten could drive up drug costs, exacerbate shortages: 5 notes
Drugmakers prep for bird flu outbreak, despite continued low risk
Heart health differences in men and women: Tiny RNA molecules play key role, study finds

Share This Article